{
    "2018-07-19": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Novartis won’t raise drug prices in US",
                "features": {
                    "keywords": [
                        "Novartis",
                        "drug prices",
                        "US"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis's Kisqali Gets FDA Nod for Label Expansion",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Kisqali",
                        "FDA",
                        "label expansion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Gilenya",
                        "generic sales",
                        "MS"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut",
                "features": {
                    "keywords": [
                        "Novartis",
                        "skin drug",
                        "licensing"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "[$$] Novartis, MorphoSys and Galapagos Shares Rise on Drug Deal",
                "features": {
                    "keywords": [
                        "Novartis",
                        "MorphoSys",
                        "Galapagos",
                        "drug deal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Swiss Stock Market Slipped Into The Red Going Into The Close",
                "features": {
                    "keywords": [
                        "Swiss stock market",
                        "slipped",
                        "red"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "European Markets Finished Mixed In Lackluster Trade",
                "features": {
                    "keywords": [
                        "European markets",
                        "mixed",
                        "trade"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Trump thanks Novartis, Pfizer for not raising drug prices",
                "features": {
                    "keywords": [
                        "Trump",
                        "Novartis",
                        "Pfizer",
                        "drug prices"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "policy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis to Pay as Much as $1 Billion for Rights to Skin Drug",
                "features": {
                    "keywords": [
                        "Novartis",
                        "skin drug",
                        "rights",
                        "$1 billion"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Galapagos",
                        "MorphoSys",
                        "skin drug",
                        "95 mln euros"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "European Shares Slide On Mixed Earnings",
                "features": {
                    "keywords": [
                        "European shares",
                        "slide",
                        "earnings"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis Buys Exclusive Rights To IL-17C Compound MOR106 For Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "Novartis",
                        "IL-17C",
                        "MOR106",
                        "atopic dermatitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "[$$] Novartis Won’t Raise U.S. Drug Prices This Year",
                "features": {
                    "keywords": [
                        "Novartis",
                        "drug prices",
                        "US"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}